ADVERTISEMENT
puts people with MS first.
the first mobile app for MS > > >
2002
2005
2006
2011
Refrigeration
Free
FDA-approved,
refrigeration-free
formulation
BENEFIT Study
Bayer completes a 2-year
study on BETASERON
(486 participants)
CIS Indication
FDA approves use in
patients with clinically
isolated syndrome
myBETAapp™
The 1st MS injection-
tracker app developed
for the iPhone® and
other smartphones
• Female patients should be warned about the
potential risk to pregnancy.
• Cases of anaphylaxis have been reported rarely.
• The most commonly reported adverse reactions
are lymphopenia (low numbers of a certain kind of
white blood cell), injection-site reaction, asthenia
(general weakness), flu-like symptom complex
(flu syndrome and/or a combination of at least
two Adverse Events from fever, chills, muscle
aches, tiredness and sweating), headache and
pain. Gradual dose titration and use of analgesics
during treatment initiation may help reduce flu-like symptoms.
See “Warnings,” “Precautions,” and “Adverse
Reactions” sections of full Prescribing Information.
More information, including the full Prescribing
Information, is available at
www.BETASERON.com.
Please see brief summary of full Prescribing
Information on the following page.
You are encouraged to report negative side
effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
*Some restrictions apply. Please visit www.BETASERON.com/
affordability or call 1-800-788-1467 for more information.
Patients who are enrolled in any type of government insurance
or reimbursement programs are not eligible. As a condition
precedent of the copayment support provided under this program,
eg, copay refunds, participating patients and pharmacies are
obligated to inform insurance companies and third-party payors of
any benefits they receive and the value of this program, as required
by contract or otherwise. Void where prohibited by law, taxed, or
restricted. Patients enrolled in Bayer’s Patient Assistance Program
are not eligible.
Reference:
1. Kappos L, Polman CH, Freedman MS, et al. Treatment with
interferon beta-1b delays conversion to clinically definite
and McDonald MS in patients with clinically isolated
syndromes. Neurology. 2006;67:1242-1249.
